Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P313

ECE2006 Poster Presentations Diabetes, metabolism and cardiovascular (174 abstracts)

Orlistat improves postprandial triglyceride metabolism in obese patients with or without diabetes

I Sahin 1 , R Bentli 1 , L Keskin 1 , C Taskapan 2 , S Senel 1 & S Yologlu 3


1Inonu University, Department of Endocrinology and Metabolism, Malatya, Turkey; 2Inonu University, Department of Biochemstry, Malatya, Turkey; 3Inonu University, Department of Biostatistics, Malatya, Turkey.


Objective: Accumulating data suggests that post-prandial hypertriglyceridemia is important in the pathogenesis and progression of atherosclerosis, and thus cardiovascular diseases. We aimed to assess the acute effect of the orlistat vs placebo on post-prandial triglyceride (TG) level in diabetic and non-diabetic obese patients.

Research Design and Methods: Study population consisted of 49 patients with obesity (25 non-diabetics, 24 diabetic). Patients were randomized to take either single dose of orlistat 120 mg (26 patients) or placebo (23 patients) before a standard mixed meal containing 50 g of fat. Plasma TG, glucose and insulin levels were measured at baseline and post-prandially at 2-h interval for 6–h. Post-prandial curves were calculated as the total area under curve (AUC) for TG. The incremental area under the curves (d AUC) for TG was also calculated.

Results: There were no statistically significant difference between the orlistat and placebo groups with regard to age, sex, BMI, A1c, basal triglyceride and basal total cholesterol. Post-prandial glucose and insulin responses to test meal were not significant between the orlistat and the placebo groups. Significant post-prandial TG reduction in TG 4-h (202.2±103.1 vs 297.5±121 mg/dl, P=0.005) and in TG 6-h (151.9±78.7 vs 233.9±93.1 mg/dl, P=0.002) were achieved with orlistat, which resulted in a significant lower TG AUC (1163.3±566.2 vs 1475.6±561.7, P=0.042) and TG dAUC (269. 7±250.7 vs 571.8±296.2 P<0.001) compared to the placebo group.

The effect of orlistat on time course of the change in postprandial TG concentrations (except TG at 6-h), TG AUC, TG dAUC during 6-h postprandial period were not different between diabetic and non-diabetic obese.

Conclusion: Orlistat improves postprandial TG concentrations in both diabetic and non-diabetic obese patients.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.